The case for biosimilars–a payer’s perspective
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
Biosimilars have the potential for making savings in healthcare costs, and with resource allocation, if competition is permitted at the level of treatment induction.
Authors and Affiliations
Gustaf Befrits
Keywords
Related Articles
- EP ID EP355077
- DOI 10.5639/gabij.2013.0201.009
- Views 106
- Downloads 0
Terminology for biosimilars–a confusing minefield
Biosimilars are firmly established in the EU as copy biologicals with a clear and effective regulatory route for approval. Unfortunately, inconsistency in nomenclature for biosimilars has caused confusion. This problem o...
Myths, questions, facts about generic drugs in the EU
Many generic drugs are now being prescribed and the trend is increasing. For example, in Austria, the number of all generics prescriptions has more than doubled from 11% in 2000 to 23% in 2010. However, many myths and qu...
Perceptions of physicians from private medical centres in Malaysia about generic medicine usage: a qualitative study
Introduction: The healthcare sector is one of the most rapidly expanding and dynamic industries in the world. Pharmaceutical expenditure is now growing faster than other components of healthcare overheads. Globally, pres...
Health authority perspective on biosimilars
Dr Brian Godman reviews Mr Gustaf Befrits’ paper on the case for biosimilars from a payer’s perspective. Biosimilars are increasingly important to payers with growing resource pressures. However, key issues need addressi...
How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria
Objective: To analyse similarities and differences between activities carried out by Austrian sickness funds to encourage more rational use of medicines, including increasing generics uptake. Methods: Semi-structured int...